Wintermute Board announces Paul Cohn's, founding investor, passing

It is with great sadness that the Wintermute Board announce the death of one of our founding investors, Paul Cohn.

Paul Cohn, a distinguished engineer and investor, passed away last month at the esteemed age of 88. Paul dedicated his career to pioneering and commercializing innovative technologies within the energy and healthcare sectors.

In 2012, Paul became the founding investor and a director at Wintermute Biomedical, a company committed to developing next-generation therapies to combat infectious diseases and improving the life of shingles sufferers. His unique ability to identify and nurture start-up companies was instrumental in advancing Wintermute's mission to address unmet medical needs.

Paul's legacy is marked by his unwavering commitment to innovation and his significant contributions to both the energy and healthcare industries. He is survived by his family, friends, and colleagues, who will remember him fondly for his visionary leadership and dedication to improving global health.

‍

‍